BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
May 04, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Mirapexin prolonged release: Phase III data

Boehringer Ingelheim GmbH, Ingelheim, Germany
Product: Mirapexin prolonged release
Business: Neurology
Molecular target: Dopamine D2 receptor; Dopamine D3 receptor
Description: Once-daily, prolonged release formulation of Mirapexin, a dopamine agonist
Indication: Treat Parkinson's...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >